Calyxo Inc. announced that as part of its ongoing efforts to broaden access to the CVAC System, the Company will leverage the upcoming AUA2025 annual meeting to showcase new clinical data and share learnings with the urology community. The Company's presence at AUA2025 includes at least eight abstracts and a variety of additional educational opportunities that will give physicians and patients more confidence in the CVAC System. Over 10,000 patients have been treated with the steerable ureteroscopic renal Evacuation (SURE) procedure using Calyxo's CVAC System.
The second-generation CVAC System was launched at the American Urological Association (AUA) 2024 Annual Meeting and has seen swift adoption among urologists to treat kidney stones. AUA2025 is taking place April 26-29 in Las Vegas. Calyxo received FDA clearance for its newly redesigned CVAC System in February 2024.
Building on over two years of real-world experience with the first-generation device and insights from a Level 1 randomized controlled trial, the CVAC System was reengineered as an all-in-one kidney stone clearance solution. The updated system integrates three unique features--microjet irrigation, simultaneous flow, and a large outflow lumen--that work in tandem with direct visualization to maximize fragment aspiration and stone removal. In the multicenter ASPIRE trial, the CVAC System demonstrated superior kidney stone clearance and significantly reduced residual stone volume (RSV) compared to traditional ureteroscopy (URS), regardless of baseline stone size.
One year post-procedure, patients treated with the CVAC System experienced fewer healthcare consumption events--including emergency department visits, hospitalizations, and retreatments--comp compared to those treated with Ureteroscopy. The study also confirmed the safety and effectiveness of the system in achieving more complete stone removal.
